Temozolomide and Capecitabine: An Effective Combination in Metastasic G2 NETs
Introduction: Treatment of neuroendocrine tumors (NETs) with chemotherapy has been validated in different studies. Recently a retrospective trial demonstrated high and durable response rate with Temozolomide and Capecitabine in 30 pancreatic NETs (pNETs).
Aim(s): To evaluate the efficacy and safety of this combination in metastatic G2 NETs.
Materials and methods: All patients with metastatic G2 NETs treated in our center with Temozolomide (150 mg/m2, days 10-14) and Capecitabine (1000 mg/m2 twice daily, days 1-14) every 28 days, both orally, from 25th October 2010 to 30th November 2012, were collected.
Conference: 10th Annual ENETSConcerence (2013)
To read the full abstract, please log into your ENETS Member account.